Join the Global Breast Cancer Movement
Save this page to myKomen
Go to myKomen
Home > Understanding Breast Cancer > Breast Facts > Breast Facts References

  


Breast Facts References

Loading...
  1. Rosen PP. Rosen’s Breast Pathology. Philadelphia: Lippincott Williams & Wilkins, 2001.
  2. Helvie MA. Chapter 11: Mammography. In: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 3rd edition. Lippincott Williams and Wilkins, 2004. 
  3. Dickson RB, Pestell RG, Lippman ME. Chapter 33: Cancer of the breast. In Devita VT, Hellman S, Rosenberg SA, editors. Cancer--Principals and Practice of Oncology, 7th edition. Philadelphia: Lippincott Williams & Wilkins, 2005.
  4. Steeg PS. Chapter 28: Control of invasion and metastasis. In: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 3rd edition. Lippincott Williams and Wilkins, 2004.
  5. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society, 2009.
  6. American Cancer Society. Cancer Facts and Figures for African Americans 2009-2010. Atlanta, GA: American Cancer Society, 2009.
  7. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 11: 198-200, 1995.
  8. Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 14: 188-90, 1996.
  9. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 64(4):963-70, 1999.
  10. Miller BA, Chu KC, Hankey BF, Ries LA. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control. 19(3):227-56, 2008.
  11. Purc-Stephenson RJ, Gorey KM. Lower adherence to screening mammography guidelines among ethnic minority women in America: a meta-analytic review. Prev Med. 46(6):479-88, 2008.
  12. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 85(22):1819-27, 1993.
  13. Ries LAG, Melbert D, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2005: Fast Stats. Bethesdsa, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2005/, 2008.
  14. Cochran SD, Mays VM, Bowen D, et al. Cancer-related risk indicators and preventive screening behaviors among lesbians and bisexual women. Am J Public Health. 91: 591-7, 2001.
  15. Case P, Austin SB, Hunter DJ, et al. Sexual orientation, health risk factors, and physical functioning in the Nurses' Health Study II. J Womens Health (Larchmt). 13(9):1033-47, 2004.
  16. Wingo PA, King J, Swan J, et al. Breast cancer incidence among American Indian and Alaska Native women: US, 1999-2004. Cancer. 113(5 Suppl):1191-202, 2008.
  17. American Cancer Society. Breast Cancer Facts and Figures 2009-2010. Atlanta, GA: American Cancer Society, 2009.
  18. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336: 1401-8, 1997.
  19. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 352: 1337-9, 1998.
  20. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 72(5):1117-30, 2003.
  21. King MC, Marks JH and Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 302: 643-6, 2003.
  22. Risch HA, McLaughlin JR, Cole DEC, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 98(23):1694-706, 2006.
  23. National Cancer Institute. What you need to know about breast cancer: Symptoms. Washington, DC, National Cancer Institute, U.S. National Institutes of Health, 2007. http://www.cancer.gov/cancertopics/wyntk/breast/page6.
  24. National Cancer Institute. Fact sheet-Paget's disease of the nipple: Questions and answers. Washington, DC, National Cancer Institute, U.S. National Institutes of Health, 2005. http://www.cancer.gov/cancertopics/factsheet/sites-types/paget-breast.
  25. American Cancer Society. Breast cancer: early detection. Atlanta, GA, American Cancer Society, 2008. http://www.cancer.org/docroot/CRI/content/CRI_2_6x_Breast_Cancer_Early_Detection.asp.
  26. Centers for Disease Control and Prevention. Cancer: Symptoms of breast cancer. Atlanta, GA, Centers for Disease Control and Prevention, 2006. http://www.cdc.gov/cancer/breast/basic_info/symptoms.htm.
  27. Rohan TE, Negassa A, Chlebowski RT, et al. Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev. 17(9):2337-43, 2008.
  28. Rohan TE, Negassa A, Chlebowski RT, et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst. 100(8):563-71, 2008.
  29. Baer HJ, Schnitt SJ, Connolly JL, et al. Adolescent diet and incidence of proliferative benign breast disease. Cancer Epidemiol Biomarkers Prev. 12(11 Pt 1):1159-67, 2003.
  30. Bertelsen L, Mellemkjaer L, Balslev E, Olsen JH. Benign breast disease among first-degree relatives of young breast cancer patients. Am J Epidemiol. 168(3):261-7, 2008.
  31. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 353(3):229-37, 2005.
  32. Santen RJ. Overview of benign breast disease. In: Rose, BD, ed. UpToDate. Waltham, MA, UpToDate, 2006.
  33. Tamimi RM, Byrne B, Baer H, et al. Benign breast disease, recent alcohol consumption, and risk of breast cancer: a nested case-control study. Breast Cancer Res. 7(4):R555-62, 2005.
  34. Webb PM, Byrne C, Schnitt SJ, et al. A prospective study of diet and benign breast disease. Cancer Epidemiol Biomarkers Prev. 13(7):1106-13, 2004.
  35. Schnitt SJ, Connolly JL. Chapter 9: Pathology of Benign Breast Disorders. In: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 3rd edition. Lippincott Williams and Wilkins, 2004.
  36. Santen RJ, Mansel MD. Benign breast disorders. N Engl J Med. 353(3):275-85, 2005.
  37. Jacobs TW, Byrne C, Colditz G, Connolly JL, Schnitt SJ. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med. 340(6):430-6, 1999.
  38. Kudva YC, Reynolds C, O'Brien T, Powell C. Oberg AL, Crotty TB. Diabetic mastopathy, or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetes. Diabetes Care. 25(1):121-6, 2002.
  39. Ravdin PM, Cronin KA, Howlander N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 356(16):1670-4, 2007.
  40. Kerlikowske K, Miglioretti DL, Buist DSM, Walker R, Carney PA for the National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 99(17):1335-9, 2007.
  41. Chlebowski RT, Kuller LH, Prentice RL, et al. for the WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 5;360(6):573-87, 2009.
  42. American Cancer Society. Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society, 2007.
  43. Niewoehner CB, Schorer AE. Gynaecomastia and breast cancer in men. BMJ. 336(7646):709-13, 2008.
  44. Gradishar WJ. Chapter 60: Male Breast Cancer. In Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 3rd edition. Lippincott, Williams and Wilkins, 2004.
  45. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 367(9510):595-604, 2006.
  46. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Breast cancer. V.1.200p. http://www.nccn.org, 2009.
  47. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 28(4):400-18, 2001.
  48. Houghton J, George WD, Cuzick J, et al. for the UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma in situ (DCIS) Working Party on behalf of DCIS Trialists in the UK, Australia, and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 362(9378):95-102, 2003.
  49. Vogel VG, Costantino JP, Wickerham DL, et al. for the National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 295(23):2727-41, 2006.
  50. Wickerham DL, Costantino JP, Vogel VG, et al. The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent Results Cancer Res. 181:113-9, 2009.
    51. Updated 10/19/09

Related Links

Visited by Others

Komen Videos